Get the latest in early clinical trials at ESMO TAT 2025, from bispecific antibodies for IO, cell therapies in solid tumours (CART, NK cells, modified TCRs, TIL therapy) to MAPkinase pathway and associated targets (KRAS G12C, MAP2K4, combos). Register now!